Evofem Biosciences, Inc. (EVFM): Total Liabilities
$89.71M
As of 2025-12-31
$90.01M
As of 2026-06-30
-2.6%
3-year compound annual growth
-3.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $89.71M | -0.6% | 2026-03-11, Balance as of period end |
| 2024-12-31 | $90.26M | +24.6% | 2026-03-11, Balance as of period end |
| 2023-12-31 | $72.47M | -25.3% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $96.96M | -31.8% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $142.09M | +30.8% | 2023-04-27, Balance as of period end |
| 2020-12-31 | $108.62M | +758.1% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $12.66M | -53.7% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $27.37M | -73.6% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $103.63M | n/a | 2019-03-01, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $89.71M | -0.6% |
| Scynexis Inc (SCYX) | 2025-12-31 | $9.65M | -72.9% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $62.93M | +21.4% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $7.11M | +1.6% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $85.85M | -19.9% |
| Alumis Inc. (ALMS) | 2025-12-31 | $110.64M | +36.8% |
| uniQure N.V. (QURE) | 2025-12-31 | $626.01M | +11.1% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $71.25M | -27.0% |
| Celularity Inc (CELU) | 2025-12-31 | $145.39M | +17.4% |
Compare EVFM, SCYX, CASIF, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗